Candriam S.C.A. Has $179.86 Million Stock Holdings in Gilead Sciences, Inc. $GILD

Candriam S.C.A. lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 7.3% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,620,397 shares of the biopharmaceutical company’s stock after purchasing an additional 110,559 shares during the period. Gilead Sciences accounts for approximately 0.9% of Candriam S.C.A.’s holdings, making the stock its 16th largest holding. Candriam S.C.A. owned about 0.13% of Gilead Sciences worth $179,864,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in Gilead Sciences by 1.6% during the second quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock worth $13,233,912,000 after acquiring an additional 1,893,401 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Gilead Sciences by 2.6% in the 2nd quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock valued at $3,231,548,000 after purchasing an additional 727,515 shares during the period. Norges Bank acquired a new stake in Gilead Sciences during the 2nd quarter worth approximately $2,150,268,000. Invesco Ltd. raised its holdings in Gilead Sciences by 33.5% during the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock worth $1,499,098,000 after buying an additional 3,394,330 shares during the period. Finally, Amundi lifted its stake in Gilead Sciences by 18.2% in the second quarter. Amundi now owns 10,467,411 shares of the biopharmaceutical company’s stock valued at $1,167,221,000 after buying an additional 1,614,355 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Up 2.1%

NASDAQ:GILD opened at $152.50 on Monday. Gilead Sciences, Inc. has a twelve month low of $93.37 and a twelve month high of $153.13. The firm has a market capitalization of $189.20 billion, a price-to-earnings ratio of 23.64, a price-to-earnings-growth ratio of 0.80 and a beta of 0.36. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The stock’s 50 day moving average price is $127.38 and its two-hundred day moving average price is $121.04.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on GILD shares. Rothschild & Co Redburn raised their price objective on shares of Gilead Sciences from $153.00 to $159.00 and gave the stock a “buy” rating in a report on Tuesday, January 20th. Cantor Fitzgerald reissued an “overweight” rating and issued a $135.00 price target on shares of Gilead Sciences in a research note on Friday, October 31st. Leerink Partners upped their price objective on Gilead Sciences from $114.00 to $146.00 and gave the stock an “outperform” rating in a research report on Friday, January 30th. Mizuho increased their price objective on Gilead Sciences from $131.00 to $140.00 and gave the stock an “outperform” rating in a report on Friday, November 21st. Finally, Truist Financial boosted their target price on Gilead Sciences from $140.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday, January 27th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $136.73.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $125.86, for a total value of $3,524,080.00. Following the completion of the transaction, the insider owned 107,193 shares of the company’s stock, valued at $13,491,310.98. This trade represents a 20.71% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Daniel Patrick O’day sold 115,640 shares of the company’s stock in a transaction dated Friday, January 23rd. The shares were sold at an average price of $135.00, for a total transaction of $15,611,400.00. Following the completion of the sale, the chief executive officer directly owned 566,698 shares in the company, valued at approximately $76,504,230. The trade was a 16.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 373,037 shares of company stock valued at $50,731,512 in the last 90 days. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.